JP2011121944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011121944A5 JP2011121944A5 JP2010273484A JP2010273484A JP2011121944A5 JP 2011121944 A5 JP2011121944 A5 JP 2011121944A5 JP 2010273484 A JP2010273484 A JP 2010273484A JP 2010273484 A JP2010273484 A JP 2010273484A JP 2011121944 A5 JP2011121944 A5 JP 2011121944A5
- Authority
- JP
- Japan
- Prior art keywords
- pik3ca
- mutation
- subject
- composition
- pten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000035772 mutation Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 101150063858 Pik3ca gene Proteins 0.000 claims description 21
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 19
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 19
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 17
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 17
- 230000004544 DNA amplification Effects 0.000 claims description 13
- 229940121935 ErbB tyrosine kinase inhibitor Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000002427 irreversible effect Effects 0.000 claims description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 7
- 229950008835 neratinib Drugs 0.000 claims description 7
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical group C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000003498 protein array Methods 0.000 claims description 5
- 238000001262 western blot Methods 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
- 108010069236 Goserelin Proteins 0.000 claims description 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
- 229940028652 abraxane Drugs 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940078010 arimidex Drugs 0.000 claims description 2
- 229940087620 aromasin Drugs 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229950006418 dactolisib Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 229940087477 ellence Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 229940087476 femara Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960002913 goserelin Drugs 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 229960000235 temsirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 229940033942 zoladex Drugs 0.000 claims description 2
- 229940115080 doxil Drugs 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229940020967 gemzar Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28582109P | 2009-12-11 | 2009-12-11 | |
| US61/285,821 | 2009-12-11 | ||
| US28787209P | 2009-12-18 | 2009-12-18 | |
| US61/287,872 | 2009-12-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051863A Division JP2015110669A (ja) | 2009-12-11 | 2015-03-16 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011121944A JP2011121944A (ja) | 2011-06-23 |
| JP2011121944A5 true JP2011121944A5 (enExample) | 2014-01-30 |
Family
ID=43628745
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010273484A Withdrawn JP2011121944A (ja) | 2009-12-11 | 2010-12-08 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2015051863A Pending JP2015110669A (ja) | 2009-12-11 | 2015-03-16 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2016120503A Withdrawn JP2016169229A (ja) | 2009-12-11 | 2016-06-17 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2017038956A Withdrawn JP2017101072A (ja) | 2009-12-11 | 2017-03-02 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2018246698A Withdrawn JP2019052187A (ja) | 2009-12-11 | 2018-12-28 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2020119091A Withdrawn JP2020169212A (ja) | 2009-12-11 | 2020-07-10 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2021192872A Pending JP2022022296A (ja) | 2009-12-11 | 2021-11-29 | ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051863A Pending JP2015110669A (ja) | 2009-12-11 | 2015-03-16 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2016120503A Withdrawn JP2016169229A (ja) | 2009-12-11 | 2016-06-17 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2017038956A Withdrawn JP2017101072A (ja) | 2009-12-11 | 2017-03-02 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2018246698A Withdrawn JP2019052187A (ja) | 2009-12-11 | 2018-12-28 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2020119091A Withdrawn JP2020169212A (ja) | 2009-12-11 | 2020-07-10 | ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー |
| JP2021192872A Pending JP2022022296A (ja) | 2009-12-11 | 2021-11-29 | ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20130189274A1 (enExample) |
| EP (2) | EP3575413A1 (enExample) |
| JP (7) | JP2011121944A (enExample) |
| CA (1) | CA2783743C (enExample) |
| WO (1) | WO2011070499A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| NZ599762A (en) | 2009-11-09 | 2014-07-25 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| CA2843222A1 (en) * | 2011-07-28 | 2013-01-31 | Genentech, Inc. | Pik3ca h1047r knock-in non-human animal breast cancer model |
| WO2013083810A1 (en) * | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| KR101915942B1 (ko) * | 2012-06-08 | 2018-11-06 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
| CN105274188A (zh) * | 2014-05-29 | 2016-01-27 | 北京雅康博生物科技有限公司 | Pik3ca基因突变检测试剂盒 |
| NZ737362A (en) * | 2015-05-15 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations |
| US10672505B2 (en) | 2015-06-03 | 2020-06-02 | General Electric Company | Biological data annotation and visualization |
| US9953133B2 (en) | 2015-06-03 | 2018-04-24 | General Electric Company | Biological data annotation and visualization |
| US9607375B2 (en) * | 2015-06-03 | 2017-03-28 | Eileen B. Gallagher | Biological data annotation and visualization |
| KR20190054826A (ko) * | 2017-11-14 | 2019-05-22 | 한미약품 주식회사 | 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도 |
| KR102871791B1 (ko) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
| IT201800010730A1 (it) * | 2018-11-30 | 2020-05-30 | Univ Degli Studi Milano | Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia |
| IL285020B2 (en) | 2019-02-06 | 2025-11-01 | Venthera Inc | Topical phosphoinositide 3-kinase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| WO2006098978A1 (en) * | 2005-03-09 | 2006-09-21 | Abbott Laboratories | Diagnostics method for identifying candidate patients for the treatment with trastuzumab |
| EP1899463A4 (en) * | 2005-05-09 | 2009-11-25 | Ariad Pharma Inc | BIOMARKERS FOR EVALUATING THE PROBABILITY OF SENSITIVITY OF A TUMOR AGAINST A MTOR INHIBITOR |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| EP1978106A1 (en) * | 2007-04-07 | 2008-10-08 | Universitätsklinikum Hamburg-Eppendorf | Detection of ESR1 amplification in endometrium cancer and ovary cancer |
| ES2529790T3 (es) * | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
-
2010
- 2010-12-06 EP EP19170821.3A patent/EP3575413A1/en active Pending
- 2010-12-06 US US13/514,556 patent/US20130189274A1/en not_active Abandoned
- 2010-12-06 CA CA2783743A patent/CA2783743C/en active Active
- 2010-12-06 EP EP10805335A patent/EP2510121A1/en not_active Ceased
- 2010-12-06 WO PCT/IB2010/055604 patent/WO2011070499A1/en not_active Ceased
- 2010-12-08 JP JP2010273484A patent/JP2011121944A/ja not_active Withdrawn
-
2015
- 2015-03-16 JP JP2015051863A patent/JP2015110669A/ja active Pending
-
2016
- 2016-04-14 US US15/099,429 patent/US20160222467A1/en not_active Abandoned
- 2016-06-17 JP JP2016120503A patent/JP2016169229A/ja not_active Withdrawn
-
2017
- 2017-03-02 JP JP2017038956A patent/JP2017101072A/ja not_active Withdrawn
-
2018
- 2018-12-28 JP JP2018246698A patent/JP2019052187A/ja not_active Withdrawn
-
2019
- 2019-05-17 US US16/416,083 patent/US20190271047A1/en not_active Abandoned
-
2020
- 2020-07-10 JP JP2020119091A patent/JP2020169212A/ja not_active Withdrawn
-
2021
- 2021-11-09 US US17/522,637 patent/US20220170107A1/en not_active Abandoned
- 2021-11-29 JP JP2021192872A patent/JP2022022296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geller et al. | Biology and treatment of rhabdoid tumor | |
| JP2024128025A (ja) | ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用 | |
| Thomas et al. | mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma | |
| JP2020062012A (ja) | 神経膠芽腫を治療するための診断方法及び組成物 | |
| Taschner-Mandl et al. | Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence | |
| Li et al. | BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer | |
| JP2011503111A (ja) | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 | |
| JP2018532992A (ja) | 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発 | |
| JP2011503071A (ja) | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療 | |
| US10876115B2 (en) | Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy | |
| De La Rosa et al. | The synergistic effect of DZ-NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells | |
| US20160208246A1 (en) | Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression | |
| Ma et al. | Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models | |
| EP4127722A2 (en) | Methods and compositions for treating cancer | |
| Liu et al. | Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence | |
| Lin et al. | Long noncoding RNA HOXA11-AS modulates the resistance of nasopharyngeal carcinoma cells to cisplatin via miR-454-3p/c-Met | |
| Brown-Burke et al. | PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma | |
| Stern et al. | Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin | |
| Fan et al. | Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity | |
| Long et al. | Resistance to PRMT5-targeted therapy in mantle cell lymphoma | |
| Cheung et al. | Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma | |
| EP3606536A1 (en) | Biomarkers indicative of prostate cancer and treatment thereof | |
| Folaron et al. | Vascular priming enhances chemotherapeutic efficacy against head and neck cancer | |
| JP6975720B2 (ja) | 腫瘍の診断および治療におけるＡｋｔ２の使用 | |
| US20220218708A1 (en) | Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer |